STOCK TITAN
  1. Home
  2. Sec-filings
  3. IGC
  4. [8-K] IGC Pharma, Inc. Reports Material Event

IGC Pharma extends $12M O-Bank credit facility

IGC Pharma, Inc. entered into an amendment with O-Bank Co., Ltd. on June 5, 2026, to extend its existing Master Loan and Security Agreement and General Banking Facility Letter.

Filing Impact
(Moderate)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
8-K

Rhea-AI Filing Summary

IGC Pharma, Inc. entered into an amendment with O-Bank Co., Ltd. on June 5, 2026, to extend its existing Master Loan and Security Agreement and General Banking Facility Letter. The banking facility continues to provide a maximum aggregate limit of $12,000,000 for the company.

Key terms remain substantially unchanged from the June 24, 2025 facility letter, except the facility fee has increased from $48,000 to $60,000. The agreement is characterized as a material definitive agreement and also creates a direct financial obligation for IGC under Item 2.03.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial
The company incurred a new significant debt or off-balance-sheet obligation.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Credit facility limit $12,000,000 Maximum aggregate limit under O-Bank General Banking Facility Letter
Prior facility fee $48,000 Facility fee under 2025 O-Bank facility letter
New facility fee $60,000 Facility fee under 2026 amended O-Bank facility
Form type 8-K Reported under Items 1.01 and 2.03
Master Loan and Security Agreement financial
"entered into an amendment to extend its existing Master Loan and Security Agreement together with the General Banking Facility Letter"
General Banking Facility Letter financial
"The Loan Agreement continues the facility arrangement previously set forth in the General Banking Facility Letter dated June 24, 2025."
material definitive agreement regulatory
"Item 1.01 Entry into a Material Definitive Agreement Extension of Master Loan and Security Agreement"
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
direct financial obligation regulatory
"Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What financing agreement did IGC (IGC) update in this 8-K?
IGC Pharma, Inc. extended its existing Master Loan and Security Agreement and General Banking Facility Letter with O-Bank Co., Ltd., maintaining access to a credit facility while largely keeping prior terms in place, aside from a higher facility fee.

What is the size of IGC Pharma’s credit facility with O-Bank?
The O-Bank facility for IGC Pharma provides a maximum aggregate limit of $12,000,000. This ceiling defines the total borrowing capacity available to the company under the extended General Banking Facility Letter and related Master Loan and Security Agreement.

How did IGC’s facility fee change in the amended O-Bank agreement?
The facility fee increased from $48,000 to $60,000 under the amended O-Bank arrangement. While the overall structure and other material terms remain substantially unchanged, this higher fee reflects the updated cost of maintaining the $12,000,000 facility.

Why is this O-Bank agreement considered a material definitive agreement for IGC?
The agreement is described as a material definitive agreement because it governs a significant $12,000,000 banking facility. Such contracts can meaningfully affect a company’s financing arrangements and are therefore reported under Item 1.01 of Form 8-K for transparency.

What additional disclosure does IGC make under Item 2.03 in this filing?
Under Item 2.03, IGC incorporates the Item 1.01 information by reference, noting that the extended O-Bank facility creates a direct financial obligation. This highlights that borrowings under the agreement represent enforceable debt commitments for the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001326205 0001326205 2026-06-05 2026-06-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 5, 2026

 

 

IGC PHARMA, INC.

(Exact name of registrant as specified in charter)

 

Maryland   001-32830   20-2760393
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (I.R.S. Employer Identification No.)

 

10224 Falls Road, Potomac, Maryland 20854

(Address of principal executive offices) (Zip Code)

 

(301) 983-0998

(Registrant’s telephone number, including area code)

 

 

(Former Name or Former Address, if Changed since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $.0001 par value   IGC   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2 of this chapter)

 

Emerging growth company ☐.

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement

 

Extension of Master Loan and Security Agreement

 

On June 5, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) entered into an amendment to extend its existing Master Loan and Security Agreement together with the General Banking Facility Letter (collectively, the “Loan Agreement”) with O-Bank Co., Ltd., a banking corporation incorporated under the laws of Taiwan, as lender (the “Lender”).

 

The Loan Agreement continues the facility arrangement previously set forth in the General Banking Facility Letter dated June 24, 2025. The facility provides for a maximum aggregate limit of $12,000,000. The material terms of the facility remain substantially unchanged from the 2025 facility letter, except that the facility fee has increased from $48,000 to $60,000.

 

The foregoing summary of the Loan Agreement is qualified in its entirety by reference to the full text of the Loan Agreement, a copy of which is filed hereto as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth in Item 1.01 is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
10.1*   2026 O-Bank General Banking Facility Letter.
10.2*   2025 O-Bank General Banking Facility Letter (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the Securities and Exchange Commission on August 14, 2025).
104   Cover Page Interactive Data File (formatted as Inline XBRL).

 

*Certain schedules or similar attachments to this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K.

 

The registrant hereby agrees to furnish supplementally to the Securities and Exchange Commission upon request a copy of any omitted schedule or attachment to this exhibit.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  IGC Pharma, Inc.
     
Dated: June 8, 2026    
  By: /s/ Ram Mukunda
    Name:  Ram Mukunda
    Title: CEO

 

2

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

37 documents

Agreements & Contracts

Other Documents

Keep reading

More on IGC

All IGC news

Trending in the feed

GRML
Greenland Mines Authorizes $20 Million Share Repurchase Program and Announces Capital Allocation Priorities Open the live feed